ABOUT this BLOG and How to use it

WELCOME to Stu's Views & MS News. A product of MS Views and News, a Not-for-Profit [501c3] organization. Founded in 2008, we provide educational Multiple Sclerosis information via live seminars and via the internet.

Key-Notes: Our live seminars average approx 60 people per educational program. Our blog is visited over 2900 times per week and our website is visited by thousands each month.

Register at our website to receive our globally transmitted Multiple Sclerosis e-newsletter, currently being received in (90) Countries.

On this blog see our Directory, Archives, recent Blog Posts & so much more. Use the Blog Search box (enter a keyword). See our Facebook information AND Links to other MS Organizations & bloggers. Scroll through entire page, to find information that could EMPOWER You. At the Bottom of this page, see informational videos and some for fun.

Disclaimer: "Stu's Views & MS News" / 'MS Views and News' does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Like this blog? - CLICK "LIKE"

Friday, July 30, 2010

Stem Cell Website to Watch

Source : The MS Foundation


People seeking stem cell treatments for various conditions now have an online resource to help them evaluate the claims of clinics and companies around the world.
 
The recently launched website, www.closerlookatstemcells.org, set up by the International Society for Stem Cell Research (ISSCR), provides information about stem cell biology as well as questions to ask clinics offering these often-experimental treatments.
 
The site will eventually contain a list of clinics that did or did not provide information to the ISSCR on issues such as whether a medical ethics committee is involved in a treatment to protect patients' rights, or whether there is oversight from a regulatory body like the FDA or the European Medicines Agency. The website is the brainchild of a task force convened by Irving Weissman, MD, director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine in California, during his tenure as president of the ISSCR, which ended earlier this month.
 
Reporting in the July 2 issue of Cell Stem Cell, members of the task force (including researchers, clinicians, ethicists, jurists, and patient advocates), said they have become increasingly aware of misleading direct-to-consumer advertising touting expensive stem cell therapies.
 
Exploiting people's hopes and fears, these ads often make exaggerated claims of efficacy, underestimate the potential risks, fail to disclose methods, and leave out information on whether the treatment is conducted with regulatory oversight, according to the authors. They said such unethical marketing "could place individual patients at risk and also jeopardize the progress of legitimate stem cell clinical translation."
 
The website set up by the ISSCR aims to give patients and their physicians the information needed to assess clinics' claims and decide whether to proceed with treatment. Using a brief form, patients are able to submit websites for investigation by the ISSCR. The results of the inquiries will be posted on the ISSCR website.


*
*
***********************************************************
"Providing You with 'MS Views and News'is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
(This will take 20-25 seconds and will empower you
 with informaton and learning)
Thank you for allowing me to help to keep you informed
****************************************************************

0 comments: